Note from Steve: Around our office, Dave Lashmet is known as the "biotech guy". He attends tons of conferences every year, and a chance encounter at a conference in Paris back in 2019 had him stumbling across one of the greatest medical breakthroughs in our lifetimes. He's followed it ever since.

And, if you haven't yet heard of the three tiny drug makers with 10x potential he's managed to pinpoint within the last eight months, now's a good time to get the full story. See Dave's memo below right away...

Dear Reader,

I'm a scientist. And for the last 20 years, I've been known around Stansberry for sticking strictly to facts and tamping down on hype.

But I'm telling you, what I found today is unprecedented.

Once-in-a-century type stuff.

I've identified FOUR companies that could start a whole new wave of medicine.

Together, they have the means to help treat and even cure a disease that affects 42% of adults in the United States.

And three of these companies are very small – around 100x smaller than companies like Pfizer or Abbott...

Which sets them up for massive potential gains – up to 1,000%, based on my research.

I've been following this story for eight solid months.

And now, I'm ready to share it with you, right here.

And give away, for free, one of the four companies that's kick-starting this incredible new medical market, which could grow to $440 billion by 2025.

You can find the details, here. Don't miss this today.

Best regards,

Dave Lashmet
Editor, Stansberry Research